| human | Q5 |
| P496 | ORCID iD | 0000-0002-0504-0664 |
| P1053 | ResearcherID | M-4482-2014 |
| P1153 | Scopus author ID | 7103041117 |
| P69 | educated at | Autonomous University of Madrid | Q788091 |
| P108 | employer | Autonomous University of Barcelona | Q43452 |
| Autonomous University of Madrid | Q788091 | ||
| Memorial Sloan Kettering Cancer Center | Q1808012 | ||
| Vall d'Hebron Hospital Universitari | Q3826080 | ||
| Catalan Institution for Research and Advanced Studies | Q5051216 | ||
| Carlos III Health Institute | Q5918335 | ||
| Hospital del Mar | Q9004969 | ||
| Frederick National Laboratory for Cancer Research | Q28405614 | ||
| Vall d'Hebron Institute of Oncology | Q81933223 | ||
| P106 | occupation | researcher | Q1650915 |
| Q54508329 | A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. |
| Q37550854 | ADAM17 as a therapeutic target in multiple diseases. |
| Q53776259 | Cancer Therapeutic Resistance: Progress and Perspectives (April 7-8, 2016 - Barcelona, Spain). |
| Q37199267 | Cancer network activity associated with therapeutic response and synergism |
| Q92859268 | Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity |
| Q35625995 | Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. |
| Q45341269 | Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. |
| Q91046381 | Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib |
| Q50145710 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. |
| Q40505812 | Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. |
| Q39216531 | Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. |
| Q40087664 | Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. |
| Q42486287 | Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. |
| Q38875168 | Effect of cellular senescence on the growth of HER2-positive breast cancers. |
| Q34736064 | Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. |
| Q90796782 | Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study |
| Q56999346 | Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion |
| Q40144433 | Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. |
| Q91087787 | Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer |
| Q112699608 | GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells |
| Q37636623 | Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer |
| Q90710806 | Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts |
| Q37777538 | HER2 Fragmentation and Breast Cancer Stratification |
| Q64069811 | HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503 |
| Q41735415 | High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. |
| Q37142882 | High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. |
| Q46681137 | Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. |
| Q39095733 | Interrogating open issues in cancer precision medicine with patient-derived xenografts. |
| Q92965702 | LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells |
| Q92947583 | MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors |
| Q48190414 | MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer |
| Q81738842 | Matrix metalloproteases and tumor invasion |
| Q37708733 | Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. |
| Q72111433 | Modulation of the Multicatalytic Proteinase Complex by Lipids, Interconversion and Proteolytic Processing |
| Q58702635 | Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy |
| Q41956426 | N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity. |
| Q27851451 | NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. |
| Q47130450 | Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis. |
| Q63979688 | PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells |
| Q48328230 | Pancreatic cancer heterogeneity and response to Mek inhibition |
| Q35663687 | Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies |
| Q38965541 | Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. |
| Q94552637 | Preclinical activity of PI3K inhibitor Copanlisib in Gastrointestinal Stromal Tumor |
| Q53822191 | Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. |
| Q52596087 | RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer. |
| Q51814356 | Recycling of cell surface pro-transforming growth factor-{alpha} regulates epidermal growth factor receptor activation. |
| Q50902443 | Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. |
| Q35939308 | Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. |
| Q54976637 | Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth. |
| Q57809682 | TGFβ-activated USP27X deubiquitinase regulates cell migration and chemoresistance via stabilization of Snail1 |
| Q92717496 | TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells |
| Q38899794 | Targeting the EGF/HER Ligand-Receptor System in Cancer. |
| Q33593917 | The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration |
| Q57837760 | The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells |
| Q91409346 | Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer |
| Q52286403 | Treating cancer's kinase 'addiction'. |
| Q58000899 | Who will benefit from treatment against EGFR? |
| Q57042030 | p95HER2-T cell bispecific antibody for breast cancer treatment |
Search more.